Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study

Jochen Zwerina; Christian Bach; Davide Martorana; Maria Jatzwauk; Guido Hegasy; Frank Moosig; Jan Bremer; Stefan Wieczorek; Alexander Moschen; Herbert Tilg; Thomas Neumann; Bernd M. Spriewald; Georg Schett; Augusto Vaglio

doi:10.1093/rheumatology/keq445

Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study

Jochen Zwerina^*, Christian Bach, Davide Martorana, Maria Jatzwauk, Guido Hegasy, Frank Moosig, Jan Bremer, Stefan Wieczorek, Alexander Moschen, Herbert Tilg, Thomas Neumann, Bernd M. Spriewald, Georg Schett, Augusto Vaglio

^*Corresponding author for this work

Clinic of Rheumatology

84 Citations (Scopus)

Abstract

Objectives. To determine the potential of eotaxin-3 as a diagnostic marker for active disease and genetic susceptibility factor for Churg-Strauss syndrome (CSS). Methods. A total of 37 patients with active, relapsed or inactive CSS, 123 healthy controls and 138 disease controls were studied. Clinical data were collected and serum levels of eotaxin-3 were determined. Ex vivo stability of eotaxin-3 in serum samples was tested. Furthermore, the association of single nucleotide polymorphisms (SNPs) in the eotaxin-3 gene with CSS was determined in 161 CSS patients and 124 healthy controls. Results. Serum eotaxin-3 was highly elevated in active CSS patients. Neither eosinophilic diseases nor other small-vessel vasculitides were associated with high serum eotaxin-3 levels. Receiver operating characteristic curve analysis determined a sensitivity and specificity of 87.5 and 98.6% at a cut-off level of 80 pg/ml. None of the tested SNPs within the eotaxin-3 gene influenced the susceptibility to develop CSS. Conclusions. Serum eotaxin-3 is a sensitive and specific marker for the diagnosis of active CSS suitable for routine clinical practice. Previously described SNPs in the eotaxin-3 gene do not predict the risk of developing CSS.

Original language	English
Article number	keq445
Journal	Rheumatology
Volume	50
Issue number	10
Pages (from-to)	1823-1827
Number of pages	5
ISSN	1462-0324
DOIs	https://doi.org/10.1093/rheumatology/keq445
Publication status	Published - 01.10.2011

Funding

Funding: This work was supported by the German Research Society (SFB 423/TP A34 to J.Z.) and the Kompetenznetzwerk Rheumatologie (Center Erlangen).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/rheumatology/keq445

Cite this

@article{c274030277ca4842b5d9495bb67877fb,

title = "Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study",

abstract = "Objectives. To determine the potential of eotaxin-3 as a diagnostic marker for active disease and genetic susceptibility factor for Churg-Strauss syndrome (CSS). Methods. A total of 37 patients with active, relapsed or inactive CSS, 123 healthy controls and 138 disease controls were studied. Clinical data were collected and serum levels of eotaxin-3 were determined. Ex vivo stability of eotaxin-3 in serum samples was tested. Furthermore, the association of single nucleotide polymorphisms (SNPs) in the eotaxin-3 gene with CSS was determined in 161 CSS patients and 124 healthy controls. Results. Serum eotaxin-3 was highly elevated in active CSS patients. Neither eosinophilic diseases nor other small-vessel vasculitides were associated with high serum eotaxin-3 levels. Receiver operating characteristic curve analysis determined a sensitivity and specificity of 87.5 and 98.6\% at a cut-off level of 80 pg/ml. None of the tested SNPs within the eotaxin-3 gene influenced the susceptibility to develop CSS. Conclusions. Serum eotaxin-3 is a sensitive and specific marker for the diagnosis of active CSS suitable for routine clinical practice. Previously described SNPs in the eotaxin-3 gene do not predict the risk of developing CSS.",

author = "Jochen Zwerina and Christian Bach and Davide Martorana and Maria Jatzwauk and Guido Hegasy and Frank Moosig and Jan Bremer and Stefan Wieczorek and Alexander Moschen and Herbert Tilg and Thomas Neumann and Spriewald, \{Bernd M.\} and Georg Schett and Augusto Vaglio",

year = "2011",

month = oct,

day = "1",

doi = "10.1093/rheumatology/keq445",

language = "English",

volume = "50",

pages = "1823--1827",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study

AU - Zwerina, Jochen

AU - Bach, Christian

AU - Martorana, Davide

AU - Jatzwauk, Maria

AU - Hegasy, Guido

AU - Moosig, Frank

AU - Bremer, Jan

AU - Wieczorek, Stefan

AU - Moschen, Alexander

AU - Tilg, Herbert

AU - Neumann, Thomas

AU - Spriewald, Bernd M.

AU - Schett, Georg

AU - Vaglio, Augusto

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Objectives. To determine the potential of eotaxin-3 as a diagnostic marker for active disease and genetic susceptibility factor for Churg-Strauss syndrome (CSS). Methods. A total of 37 patients with active, relapsed or inactive CSS, 123 healthy controls and 138 disease controls were studied. Clinical data were collected and serum levels of eotaxin-3 were determined. Ex vivo stability of eotaxin-3 in serum samples was tested. Furthermore, the association of single nucleotide polymorphisms (SNPs) in the eotaxin-3 gene with CSS was determined in 161 CSS patients and 124 healthy controls. Results. Serum eotaxin-3 was highly elevated in active CSS patients. Neither eosinophilic diseases nor other small-vessel vasculitides were associated with high serum eotaxin-3 levels. Receiver operating characteristic curve analysis determined a sensitivity and specificity of 87.5 and 98.6% at a cut-off level of 80 pg/ml. None of the tested SNPs within the eotaxin-3 gene influenced the susceptibility to develop CSS. Conclusions. Serum eotaxin-3 is a sensitive and specific marker for the diagnosis of active CSS suitable for routine clinical practice. Previously described SNPs in the eotaxin-3 gene do not predict the risk of developing CSS.

AB - Objectives. To determine the potential of eotaxin-3 as a diagnostic marker for active disease and genetic susceptibility factor for Churg-Strauss syndrome (CSS). Methods. A total of 37 patients with active, relapsed or inactive CSS, 123 healthy controls and 138 disease controls were studied. Clinical data were collected and serum levels of eotaxin-3 were determined. Ex vivo stability of eotaxin-3 in serum samples was tested. Furthermore, the association of single nucleotide polymorphisms (SNPs) in the eotaxin-3 gene with CSS was determined in 161 CSS patients and 124 healthy controls. Results. Serum eotaxin-3 was highly elevated in active CSS patients. Neither eosinophilic diseases nor other small-vessel vasculitides were associated with high serum eotaxin-3 levels. Receiver operating characteristic curve analysis determined a sensitivity and specificity of 87.5 and 98.6% at a cut-off level of 80 pg/ml. None of the tested SNPs within the eotaxin-3 gene influenced the susceptibility to develop CSS. Conclusions. Serum eotaxin-3 is a sensitive and specific marker for the diagnosis of active CSS suitable for routine clinical practice. Previously described SNPs in the eotaxin-3 gene do not predict the risk of developing CSS.

UR - https://www.scopus.com/pages/publications/80053137236

U2 - 10.1093/rheumatology/keq445

DO - 10.1093/rheumatology/keq445

M3 - Journal articles

C2 - 21266446

AN - SCOPUS:80053137236

SN - 1462-0324

VL - 50

SP - 1823

EP - 1827

JO - Rheumatology

JF - Rheumatology

IS - 10

M1 - keq445

ER -

Eotaxin-3 in Churg-Strauss syndrome: A clinical and immunogenetic study

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this